KALARIS THERAPEUTICS, INC. Retained Earnings
KALARIS THERAPEUTICS, INC. (KLRS) had Retained Earnings of -$182.37 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$182.37M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$170.85M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$160.00M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$150.00M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$182.37M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$170.85M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$160.00M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | -$150.00M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$138.11M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$126.76M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$116.56M 10-K · filed 2026-03-17 | -$714.96M 10-K · filed 2025-03-07 |
| 2024-09-30 | -$696.69M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$692.57M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | -$686.49M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -$656.19M 10-K · filed 2025-03-07 | |
| 2023-09-30 | -$596.50M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | -$552.23M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$506.96M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$465.77M 10-K · filed 2024-03-15 | |
| 2022-09-30 | -$427.64M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | -$385.57M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$385.60M 10-Q · filed 2022-08-04 | -$340.93M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$297.06M 10-K · filed 2023-02-15 | |
| 2021-09-30 | -$239.12M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | -$193.61M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | -$156.03M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | -$125.10M 10-K · filed 2022-02-10 | |
| 2020-09-30 | -$99.90M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | -$76.29M 10-Q · filed 2020-09-02 | |
| 2019-12-31 | -$55.32M 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |